Related Experiment Video
Updated: Jun 21, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
[Stroke and renin-angiotensin system].
1Department of Neurology, Saitama Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 14, 2006
Summary
Angiotensin II contributes to hypertension and ischemic stroke. Inhibiting the renin-angiotensin system, independent of blood pressure, shows promise for stroke prevention.
Area of Science:
- Cardiovascular Research
- Neuroscience
- Pharmacology
Background:
- Angiotensin II is central to hypertension and ischemic stroke pathogenesis.
- Activation of angiotensin II type 1 (AT1) receptors promotes vasoconstriction and inflammation via NADPH oxidase.
- Angiotensin II type 2 (AT2) receptors may offer protective effects.
Purpose of the Study:
- To explore the role of the renin-angiotensin system in ischemic stroke.
- To evaluate the efficacy of renin-angiotensin system inhibition in stroke prevention.
Main Methods:
- Review of clinical trials investigating AT1 receptor blockers and ACE inhibitors.
- Analysis of the impact of renin-angiotensin system inhibition on stroke prevention outcomes.
Main Results:
- Clinical trials demonstrate beneficial effects of AT1 receptor blockers and ACE inhibitors on stroke prevention.
- These benefits appear independent of significant blood pressure reduction.
Conclusions:
- Inhibition of the renin-angiotensin system is a promising strategy for preventing ischemic stroke.
- Targeting the renin-angiotensin system offers stroke prevention benefits beyond blood pressure control.
Related Concept Videos
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...